Dr. Russell Katz, MD, Director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research (CDER) agrees with the logic. In 2013 he stated:
The scientific community and the FDA believe that it is critical to identify and study patients with very early Alzheimer's disease before there is too much irreversible injury to the brain. It is in this population that most researchers believe that new drugs have the best chance of providing meaningful benefit to patients." We believe this reinforces the need and desire for early-stage detection, and the potential multi-hundred million dollar opportunity that LymPro represents.

We're getting closer....